ResMed Shares Fall 9.2% Amid Nine-Day Losing Streak

ResMed (RMD) shares fell for the ninth straight trading day, resulting in a cumulative decline of 9.2% and a reduction in market capitalization of approximately $3.2 billion. The company's market value now stands at roughly $32 billion, with the stock trading at $218.27 per share as of September 11, 2026. This price level sits significantly closer to the 52-week low of $182.30 than the high of $280.31, marking a distinct divergence from the broader market where the S&P 500 returned -0.7% over the same nine-day period.

According to data from GN stocks/sp500, the recent slide contrasts with the company's underlying business performance. ResMed’s trailing twelve-month revenue grew by 9.9%, exceeding the S&P 500 median of 8.3%, while its operating margin reached 33.8% compared to the index median of 18.6%. Despite these operational strengths, the stock now trades at a price-to-earnings multiple of 20.7, which is below the 25.1 median for the S&P 500 Health Care sector, suggesting the market is currently discounting the firm's relative value.

Operational Metrics Outpace Sector Medians

The company maintains a three-year average annual revenue growth rate of 10.2% and generates a free cash flow yield of 5.2%. These figures indicate a consistent trajectory of expansion and cash generation that remains intact despite the recent price action. The disconnect between the share price and these core financial indicators highlights a specific valuation gap that distinguishes ResMed from other S&P 500 constituents currently experiencing similar multi-day losing streaks.

Valuation Gap Reflects Market Sentiment

ResMed’s year-to-date performance in 2026 shows an 8.6% decline, lagging the S&P 500’s 11.9% gain, although the stock delivered a 34.2% return in 2024. The recent nine-day losing streak is part of a broader trend where the stock underperformed the index over one-month and year-to-date periods. The current trading multiple below sector peers suggests investors are prioritizing short-term price momentum over the company's established profitability and growth metrics.

Fundamental Stability Persists Amid Price Drop

The decline does not appear to be driven by a deterioration in the company’s trailing operating results. With an operating margin nearly double the sector median and revenue growth leading the index, the business fundamentals remain robust. The current share price reflects a market adjustment rather than a change in the company’s core financial standing, leaving the valuation at a level that is lower than the broader healthcare sector average.